65,437 trials
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 10; 10 Participants
Myelodysplastic Syndrome · Chronic Myelomonocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Percentage of Participants Who Are Able to Stop Prophylactic Tacrolimus (D90 Cohort) — 33 Participants
HIV
Primary: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period — .64; .23; .36; .77…
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 — 108; 8 Participants — p=<0.0001
Non-small Cell Lung Cancer
Primary: Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis — 8.0; 6.9 Percentage of Participants
Psoriasis
Primary: Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16 — 52; 0; 4 Participants
Atopic Dermatitis
Primary: DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12 — -47.71; -32.98 percent change — p=<0.001
Fragile X Tremor/Ataxia Syndrome
Primary: FXTAS Rating Scale Score — 45.8 score on a scale
Psoriasis
Primary: The Percentage of Participants With sPGA Response of 0 or 1 — 55.6; 6.8 Percentage of participants — p=<0.0001
Breast Cancer · Breast Diseases
Primary: Comparing the Area Under the LROC Curve — 0.7786; 0.8160 probability — p=<0.05
Solid Tumor
Primary: Number of Participants With Adverse Events Due to MSOT Imaging — 0 Participants
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Primary: Raynaud's Symptom Severity (Change From Baseline) — -20.19; -18.63 score on a scale
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.20; -1.26 Percentage of HbA1c
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Preterm Birth
Primary: Feasibility as Measured by Number of Recruited Eligible Patients Enrolled — 30 Participants